Zurich, Switzerland — September 13, 2025 — Santersus AG congratulates its alliance partner OrganOx Ltd on the company’s acquisition by Terumo Corporation in a transaction valued at up to $1.5 billion — a major milestone in the evolution of global transplant technologies.
OrganOx is a leader in normothermic machine perfusion (NMP) for liver transplantation, with its Metra® system adopted in centers worldwide. This technology improves the viability of donor livers, increases utilization of extended criteria donors (ECD), and reduces post-transplant complications — reflecting growing global demand for advanced organ preservation and recovery platforms.
Reconditioning of extended criteria donor livers is part of Santersus’s broader clinical pipeline for NucleoCapture®. Among five lead indications, two — sepsis and systemic lupus erythematosus (SLE) — have already received Breakthrough Device Designation from the U.S. FDA, highlighting the potential of NET-targeting approaches in both acute and immune-mediated diseases.
As Santersus advances clinical development programs in critical care, autoimmune diseases, organ transplantation, and neurodegeneration, the company remains committed to realizing the full potential of NucleoCapture® treatment.
For more information, visit www.santersus.com or explore our dedicated liver transplantation program page.